BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

211 related articles for article (PubMed ID: 30662082)

  • 41. The impact of 10 years of human papillomavirus (HPV) vaccination in Australia: what additional disease burden will a nonavalent vaccine prevent?
    Patel C; Brotherton JM; Pillsbury A; Jayasinghe S; Donovan B; Macartney K; Marshall H
    Euro Surveill; 2018 Oct; 23(41):. PubMed ID: 30326995
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Risk of human papillomavirus infection in women with rheumatic disease: cervical cancer screening and prevention.
    Kim SC; Feldman S; Moscicki AB
    Rheumatology (Oxford); 2018 Jul; 57(suppl_5):v26-v33. PubMed ID: 30137592
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Knowledge and acceptability of human papillomavirus vaccination and cervical cancer screening among women in Karnataka, India.
    Montgomery MP; Dune T; Shetty PK; Shetty AK
    J Cancer Educ; 2015 Mar; 30(1):130-7. PubMed ID: 25355525
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Can male vaccination reduce the burden of human papillomavirus-related disease in the United States?
    Low GM; Attiga YS; Garg G; Schlegal R; Gallicano GI
    Viral Immunol; 2012 Jun; 25(3):174-86. PubMed ID: 22691099
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Integrating HPV vaccination programs with enhanced cervical cancer screening and treatment, a systematic review.
    Wirtz C; Mohamed Y; Engel D; Sidibe A; Holloway M; Bloem P; Kumar S; Brotherton J; Reis V; Morgan C
    Vaccine; 2022 Mar; 40 Suppl 1():A116-A123. PubMed ID: 34863615
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Human papillomavirus prevalence and type-distribution, cervical cancer screening practices and current status of vaccination implementation in Central and Eastern Europe.
    Poljak M; Seme K; Maver PJ; Kocjan BJ; Cuschieri KS; Rogovskaya SI; Arbyn M; Syrjänen S
    Vaccine; 2013 Dec; 31 Suppl 7():H59-70. PubMed ID: 24332298
    [TBL] [Abstract][Full Text] [Related]  

  • 47. The Vaccine and Cervical Cancer Screen project 2 (VACCS 2): Linking cervical cancer screening to a two-dose HPV vaccination schedule in the South-West District of Tshwane, Gauteng, South Africa.
    Snyman LC; Dreyer G; Visser C; Botha MH; van der Merwe FH
    S Afr Med J; 2015 Mar; 105(3):191-4. PubMed ID: 26294825
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Human papillomavirus vaccines: who will pay, who will receive, when to administer?
    Saslow D; Wheeler CM
    Ethn Dis; 2007; 17(2 Suppl 2):S2-8-13. PubMed ID: 17684807
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Comparison of different human papillomavirus (HPV) vaccine types and dose schedules for prevention of HPV-related disease in females and males.
    Bergman H; Buckley BS; Villanueva G; Petkovic J; Garritty C; Lutje V; Riveros-Balta AX; Low N; Henschke N
    Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31755549
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Knowledge, attitude and practice towards cervical cancer prevention among mothers of girls aged between 9 and 14 years: a cross sectional survey in Zimbabwe.
    Zibako P; Tsikai N; Manyame S; Ginindza TG
    BMC Womens Health; 2021 Dec; 21(1):426. PubMed ID: 34930221
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cervical cancer: screening and prevention.
    Behtash N; Mehrdad N
    Asian Pac J Cancer Prev; 2006; 7(4):683-6. PubMed ID: 17250453
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Impact of HPV vaccination on HPV infection and cervical related disease burden in real-world settings (HPV-RWS): protocol of a prospective cohort.
    Liu Z; Li P; Zeng X; Yao X; Sun Y; Lin H; Shen P; Sun F; Zhan S
    BMC Public Health; 2022 Nov; 22(1):2117. PubMed ID: 36401179
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cervical cancer in Zimbabwe: a situation analysis.
    Kuguyo O; Matimba A; Tsikai N; Magwali T; Madziyire M; Gidiri M; Dandara C; Nhachi C
    Pan Afr Med J; 2017; 27():215. PubMed ID: 28979617
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Public health impact and cost-effectiveness of switching from bivalent to nonavalent vaccine for human papillomavirus in Norway: incorporating the full health impact of all HPV-related diseases.
    Diakite I; Nguyen S; Sabale U; Pavelyev A; Saxena K; Tajik AA; Wang W; Palmer C
    J Med Econ; 2023; 26(1):1085-1098. PubMed ID: 37608730
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Human papillomavirus genotype distribution and socio-behavioural characteristics in women with cervical pre-cancer and cancer at the start of a human papillomavirus vaccination programme: the CIN3+ plus study.
    Egli-Gany D; Spaar Zographos A; Diebold J; Masserey Spicher V; Frey Tirri B; Heusser R; Dillner J; Petignat P; Sahli R; Low N;
    BMC Cancer; 2019 Jan; 19(1):111. PubMed ID: 30700274
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Primary Care Physicians' Adherence to Expert Recommendations for Cervical Cancer Screening and Prevention in the Context of Human Papillomavirus Vaccination.
    Malo TL; Perkins RB; Lee JH; Vadaparampil ST
    Sex Transm Dis; 2016 Jul; 43(7):438-44. PubMed ID: 27322046
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comprehensive control of human papillomavirus infections and related diseases.
    Bosch FX; Broker TR; Forman D; Moscicki AB; Gillison ML; Doorbar J; Stern PL; Stanley M; Arbyn M; Poljak M; Cuzick J; Castle PE; Schiller JT; Markowitz LE; Fisher WA; Canfell K; Denny LA; Franco EL; Steben M; Kane MA; Schiffman M; Meijer CJ; Sankaranarayanan R; Castellsagué X; Kim JJ; Brotons M; Alemany L; Albero G; Diaz M; de Sanjosé S;
    Vaccine; 2013 Dec; 31 Suppl 5():F1-31. PubMed ID: 24331745
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Innovations in HPV vaccination and roles of nurses in cervical cancer prevention.
    Yildirim JG; Arabaci Z
    Asian Pac J Cancer Prev; 2014; 15(23):10053-6. PubMed ID: 25556424
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Roles of extended human papillomavirus genotyping and multiple infections in early detection of cervical precancer and cancer and HPV vaccination.
    Song F; Yan P; Huang X; Wang C; Du H; Qu X; Wu R
    BMC Cancer; 2022 Jan; 22(1):42. PubMed ID: 34991494
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Prevalence and Distribution of Vaccine-Preventable Genital Human Papillomavirus(HPV) Genotypes in Ghanaian Women Presenting for Screening.
    Donkoh ET; Asmah RH; Agyemang-Yeboah F; Dabo EO; Wiredu EK
    Cancer Control; 2022; 29():10732748221094721. PubMed ID: 35536890
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.